Grey Matter Neurosciences, a neurotechnology company focusing on brain function restoration, has secured $14 million in seed financing to develop and test an ultrasound headset for Alzheimer's disease patients. The funding round was led by the Wittington Innovation Fund, with participation from Toronto Innovation Acceleration Partners, Ontario Brain Institute, and Ontario's Life Sciences Innovation Fund.
The company's approach centers on portable ultrasound helmet technology utilizing transcranial focused-ultrasound, a technology invented by Kullervo Hynynen at Sunnybrook Research Institute. The seed funding will support advanced research in focused ultrasound neuromodulation, including the construction of a specialized headset and clinical trials to evaluate both safety and feasibility. A key focus of the trials will be assessing the technology's ability to improve cognitive performance and memory sustainably.
Jeffrey Coull, founder and CEO of Grey Matter, highlighted the significance of their approach: "Generally speaking, there are no marketed therapies that can significantly and sustainably enhance cognitive function in individuals with dementia. I believe that our technology, which can reach the deepest recesses of the brain that control memory and learning, holds massive potential to boost cognition and, more generally, revolutionize how Alzheimer's and other diseases of the brain are treated."
The company has strengthened its leadership structure with the addition of new board members, including Jim Orlando, managing partner of Wittington Ventures; Lara O'Donnell, executive director of the Weston Family Foundation; and Andy Smith, president and CEO of Sunnybrook Health Sciences Centre. Parimal Nathwani, president and CEO of Toronto Innovation Acceleration Partners, will join as a board observer.
Grey Matter enters a growing field of neurotechnology companies developing innovative solutions for brain disorders. The sector has seen significant activity in 2024, with companies like Soterix Medical receiving FDA clearance for its Intraoperative Neurophysiologic Monitoring system, NaviFUS partnering with Bracco to enhance blood-brain barrier treatments, and Sonic Concepts acquiring ultrasound neuromodulation patents. Additionally, Carthera has initiated a Phase 2a clinical trial using its SonoCloud-9 device for glioblastoma treatment.
Click here for the original news story.